The Female Hormone Panel™ (FHP™) is a dynamic mapping of the free-fraction levels of estradiol (E2) and progesterone (P) throughout one cycle. The panel also includes a cycle average value for free testosterone and DHEA/DHEA-S. This panel uses 11 saliva samples collected during specified time slots throughout a menstrual cycle. The expanded panel version includes five additional FSH and LH measurements.

Download .PDF Brochure:

(right click to save)

The Female Hormone Panel: Provider Overview

FHP™ Overview

The FHP™ is used to identify menstrual cycle deficits and imbalances in progesterone, estrogen, testosterone and DHEA/DHEA-S. This panel provides a profile of the hormone fluctuations in a woman’s cycle for test-guided BHRT. The FHP™ test is most applicable in cycling women with any of the following conditions:

  • Weight gain.
  • Functional infertility.
  • Osteoporosis.
  • Endometriosis and ovarian cysts.
  • Fibroids and fibrocystic breasts.
  • Increased risk of breast cancer.
  • Recurrent cycle-related symptoms and irregularities, such as PMS, migraines, breast tenderness, emotional and cognitive issues, insomnia and spotting.

Representation of Hormone Cycle

Phases of Female Cycle

Clinical Applications

Customize BHRT

Presently hormone therapy is very empirical, and a one-size-fits-all approach is applied to most women. Due to variability among women, and the natural cyclical changes of hormones, a more frequent sampling is needed for proper hormone quantification. A single sample taken between day 20 and 22 of a cycle is less than 50% accurate. The Female Hormone Panel remedies this shortcoming by using a schedule for 11 samples distributed over a full cycle - start to end.

The FHP report includes 11 estradiol (E2) and 11 progesterone (P) measurements, cycle average DHEA/DHEA-S and testosterone, three progesterone production indices, four estradiol production indices, a full-cycle P/E ratio graph and an example of a restorative plan.

Assess Risk of Breast and Uterine Distress

It is universally accepted that there is an increased risk of proliferative disease in breast and endometrial tissue when estrogen is overly dominant. The FHP basic and expanded reports both include the follicular estrogen priming index (EΠ), which quantifies the impact of excess estradiol in menstruating women. Treatment recommendations are routinely offered in the report.

Please note that certain estrogen metabolites are falsely promoted as risk markers for breast cancer. A recent study which compared 2/16 hydroxyestrone ratio in women with breast cancer to a control group of cancer-free women concluded that there is no support for the hypothesis that the ratio of 2/16 hydroxyestrone is an important risk factor for breast cancer.
(J Nat'l Cancer Inst 1999 Jun 16:91(12):1067-72)